Renaud La Joie

Jan 15, 2025 | medrxiv.org | Daniel R. Schonhaut |Renaud La Joie

DRS has nothing to disclose, RLJ consulted for GE Healthcare. AVID Radiopharmaceuticals & Life Molecular Imaging enabled the use of Flortaucipir & Florbetaben but did not provide direct funding and were not involved in data analysis or interpretation. NIH/NIA, Alzheimer's Association, US Department of DefenceI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Mar 1, 2024 | nature.com | Joseph Therriault |Suzanne Schindler |Gemma Salvadó |Thomas K. Karikari |Melissa Murray |Inge M.W. Verberk | +5 more

AbstractDisease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD. Current in vivo diagnostic frameworks for AD are based on abnormal concentrations of amyloid-β and tau in the cerebrospinal fluid or on PET scans, and breakthroughs in molecular imaging have opened up the possibility of in vivo staging of AD.